- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library
 |
 |
epidermal growth factor receptor 2 (HER2) antibody and antigen (Recombinant protein)
Diagnostic epidermal growth factor receptor 2 (HER2) antibodies (anti-epidermal growth factor receptor 2, anti-HER2) and antigens (recombinant epidermal growth factor receptor 2 (HER2) protein) for Cancer HER2 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to
Neurodegenerative diseases diagnostics
products collection
>>
Product information
| Catalog No. | Description | US $ Price (per mg) |
|---|---|---|
| GMP-h-HER2-Ag01 | Recombinant human ERBB2/HER2/MLN19 Protein | 3090 |
| GMP-h-HER2-Ab01 | Anti-human ERBB2/HER2/MLN19 mouse monoclonal antibody (mAb) | 1953 |
| GMP-h-HER2-Ab02 | Anti-human ERBB2/HER2/MLN19 mouse monoclonal antibody (mAb) | 1953 |
| GMP-h-HER2-Ab03 | Anti-human ERBB2/HER2/MLN19 human monoclonal antibody (mAb) | 1953 |
| GMP-h-HER2-Ab04 | Anti-human ERBB2/HER2/MLN19 human monoclonal antibody (mAb) | 1953 |
Size： 1mg | 10mg | 100mg
Product Description
| Cat No. of Products | GMP-h-HER2-Ag01 |
| Product Name | Recombinant human ERBB2/HER2/MLN19 Protein |
| Target/Biomarker | epidermal growth factor receptor 2(HER2) |
| Alias of Target/Biomarker | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) |
| Expression platform | mammalian |
| Isotypes | Recombinant Antigen |
| Bioactivity validation | epidermal growth factor receptor 2 (HER2) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HER2 level test of Cancer (breast cancer) and related syndrome evaluation. |
| Products description | Recombinant human ERBB2/HER2/MLN19 Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Products | GMP-h-HER2-Ab01, GMP-h-HER2-Ab02 |
| Product Name | Anti-human ERBB2/HER2/MLN19 mouse monoclonal antibody (mAb) |
| Target/Biomarker | epidermal growth factor receptor 2(HER2) |
| Alias of Target/Biomarker | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) |
| Expression platform | CHO |
| Isotypes | Mouse IgG |
| Bioactivity validation | Human epidermal growth factor receptor 2 (HER2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other epidermal growth factor receptor 2 (HER2) antibodies in HER2 level test of Cancer (breast cancer) and related syndrome evaluation. |
| Tag | mFc |
| Products description | Anti-human ERBB2/HER2/MLN19 mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Products | GMP-h-HER2-Ab03, GMP-h-HER2-Ab04 |
| Product Name | Anti-human ERBB2/HER2/MLN19 human monoclonal antibody (mAb) |
| Target/Biomarker | epidermal growth factor receptor 2(HER2) |
| Alias of Target/Biomarker | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) |
| Expression platform | CHO |
| Isotypes | Human lgG1 |
| Bioactivity validation | Human epidermal growth factor receptor 2 (HER2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other epidermal growth factor receptor 2 (HER2) antibodies in HER2 level test of Cancer (breast cancer) and related syndrome evaluation. |
| Tag | hFc |
| Products description | Anti-human ERBB2/HER2/MLN19 human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
HER2 is a member of the human?epidermal growth factor receptor (HER/EGFR/ERBB) family.?Amplification?or over-expression of this?oncogene?has been shown to play an important role in the development and progression of certain aggressive types of?breast cancer. In recent years the protein has become an important?biomarker?and target of therapy for approximately 30% of?breast cancer?patients. It contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Facebook
LinkedIn
Twitter
Comments